XML 40 R21.htm IDEA: XBRL DOCUMENT
v3.22.4

Goodwill and intangible assets | 12 Months Ended
--- | ---
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and other intangible assets | Goodwill and other intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in millions):
| December 31,
| 2022 |  | 2021
Beginning balance | $ | 14,890 |  |  | $ | 14,689 |
Changes to goodwill resulting from acquisitions and divestitures, net(1) | 651 |  |  | 251 |
Currency translation adjustments | (12) |  |  | (50) |
Ending balance | $ | 15,529 |  |  | $ | 14,890 |
____________ (1) For 2022, the changes to goodwill consist of goodwill resulting from the acquisition of ChemoCentryx, changes to the acquisition date fair values of net assets acquired in the acquisition of Teneobio and the nonstrategic Gensenta divestiture. See Note 2, Acquisitions and divestitures. Other intangible assets Other intangible assets consisted of the following (in millions):
| December 31,
| 2022 |  | 2021
| Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net
Finite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
Developed-product-technology rights | $ | 29,028 |  |  | $ | (15,045) |  |  | $ | 13,983 |  |  | $ | 25,561 |  |  | $ | (12,769) |  |  | $ | 12,792 |
Licensing rights | 3,864 |  |  | (3,123) |  |  | 741 |  |  | 3,807 |  |  | (2,973) |  |  | 834 |
Marketing-related rights | 1,326 |  |  | (1,167) |  |  | 159 |  |  | 1,354 |  |  | (1,112) |  |  | 242 |
R&D technology rights | 1,378 |  |  | (1,190) |  |  | 188 |  |  | 1,377 |  |  | (1,133) |  |  | 244 |
Total finite-lived intangible assets | 35,596 |  |  | (20,525) |  |  | 15,071 |  |  | 32,099 |  |  | (17,987) |  |  | 14,112 |
Indefinite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
IPR&D | 1,009 |  |  | — |  |  | 1,009 |  |  | 1,070 |  |  | — |  |  | 1,070 |
Total other intangible assets | $ | 36,605 |  |  | $ | (20,525) |  |  | $ | 16,080 |  |  | $ | 33,169 |  |  | $ | (17,987) |  |  | $ | 15,182 |
Developed-product-technology rights consists of rights related to marketed products acquired in acquisitions. Licensing rights consists primarily of contractual rights acquired in acquisitions to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. R&D technology rights pertains to technologies used in R&D that have alternative future uses. Developed-product-technology rights include assets acquired with the ChemoCentryx acquisition. IPR&D, R&D technology rights and licensing rights includes assets acquired with the Teneobio acquisition. See Note 2, Acquisitions and divestitures. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. All IPR&D projects have major risks and uncertainties associated with the timely and successful completion of the development and commercialization of product candidates, including our ability to confirm safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not permitted to market a human therapeutic without obtaining regulatory approvals, and such approvals require the completion of clinical trials that demonstrate that a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans as well as competitive product launches, affect the revenues a product can generate. Consequently, the eventual realized values, if any, of acquired IPR&D projects may vary from their estimated fair values. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the years ended December 31, 2022, 2021 and 2020, we recognized amortization associated with our finite-lived intangible assets of $2.6 billion, $2.6 billion and $2.8 billion, respectively. Amortization of intangible assets is included primarily in Cost of sales in the Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the years ending December 31, 2023, 2024, 2025, 2026 and 2027, are $2.8 billion, $2.7 billion, $2.5 billion, $2.1 billion and $2.1 billion, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration